AU2020232314C1 - Pharmaceutical compositions for treating ocular diseases or disorders - Google Patents

Pharmaceutical compositions for treating ocular diseases or disorders Download PDF

Info

Publication number
AU2020232314C1
AU2020232314C1 AU2020232314A AU2020232314A AU2020232314C1 AU 2020232314 C1 AU2020232314 C1 AU 2020232314C1 AU 2020232314 A AU2020232314 A AU 2020232314A AU 2020232314 A AU2020232314 A AU 2020232314A AU 2020232314 C1 AU2020232314 C1 AU 2020232314C1
Authority
AU
Australia
Prior art keywords
biodegradable
pharmaceutical composition
weight
lactide
polymer matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020232314A
Other languages
English (en)
Other versions
AU2020232314A1 (en
AU2020232314B2 (en
Inventor
Sanjib Kumar Das
Cheng-Wen Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AU2020232314A1 publication Critical patent/AU2020232314A1/en
Publication of AU2020232314B2 publication Critical patent/AU2020232314B2/en
Application granted granted Critical
Publication of AU2020232314C1 publication Critical patent/AU2020232314C1/en
Assigned to ALCON INC. reassignment ALCON INC. Request for Assignment Assignors: AERIE PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AU2020232314A 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders Active AU2020232314C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814198P 2019-03-05 2019-03-05
US62/814,198 2019-03-05
PCT/US2020/021136 WO2020181060A1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders

Publications (3)

Publication Number Publication Date
AU2020232314A1 AU2020232314A1 (en) 2021-09-30
AU2020232314B2 AU2020232314B2 (en) 2023-10-12
AU2020232314C1 true AU2020232314C1 (en) 2024-03-28

Family

ID=72337143

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020232314A Active AU2020232314C1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders

Country Status (10)

Country Link
US (1) US12478577B2 (enExample)
EP (1) EP3934646A4 (enExample)
JP (3) JP7570342B2 (enExample)
KR (1) KR20210135560A (enExample)
CN (3) CN118286445A (enExample)
AU (1) AU2020232314C1 (enExample)
BR (1) BR112021017436A2 (enExample)
CA (1) CA3132635A1 (enExample)
MX (2) MX2021010599A (enExample)
WO (1) WO2020181060A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021010599A (es) 2019-03-05 2021-12-10 Aerie Pharmaceuticals Inc Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.
DK3861985T3 (da) 2020-02-06 2023-07-24 Ocular Therapeutix Inc Sammensætninger og fremgangsmåder til behandling af øjensygdomme
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2021207486A1 (en) * 2020-04-08 2021-10-14 Aerie Pharmaceuticals, Inc. Treatments
JP2024515826A (ja) 2021-04-30 2024-04-10 パフューズ セラピューティクス， インコーポレイテッド 眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム
WO2022235906A1 (en) 2021-05-05 2022-11-10 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
IL322360A (en) 2023-04-11 2025-09-01 Ocular Therapeutix Inc Intraocular implant containing axitinib iv polymorph
WO2025146683A1 (en) 2024-01-03 2025-07-10 Lyotropic Delivery Systems Ltd. Topical formulations for delivery of an active compound to the back of the eye
WO2025169089A1 (en) 2024-02-05 2025-08-14 Sun Pharmaceutical Industries Limited Ophthalmic compositions of tyrosine kinase inhibitors and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2704748A1 (en) * 2011-05-02 2014-03-12 DSM IP Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
US9798189B2 (en) * 2010-06-22 2017-10-24 Toyobo Co., Ltd. Liquid crystal display device, polarizer and protective film
EP3233067A1 (en) * 2014-12-18 2017-10-25 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019645A4 (en) * 2006-05-02 2013-03-06 Medivas Llc RELEASE OF OPHTHALMOLOGICAL ACTIVITIES OUTSIDE OR WITHIN THE EYE
EP2265262A1 (en) * 2008-04-25 2010-12-29 DSM IP Assets B.V. Particles comprising polymers with thioester bonds
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20130330383A1 (en) * 2010-12-29 2013-12-12 I Therapeutics, Llc Ocular drug delivery system
US20140179802A1 (en) * 2011-05-02 2014-06-26 Dsm Ip Assets B.V. Fiber comprising a biodegradable polymer
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
WO2014053542A1 (en) 2012-10-02 2014-04-10 Dsm Ip Assets B.V. Drug delivery composition comprising proteins and biodegradable polyesteramides
CA2886335C (en) 2012-10-24 2021-06-08 Dsm Ip Assets B.V. Fibers comprising polyesteramide copolymers for drug delivery
JP6511401B2 (ja) * 2013-02-15 2019-05-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続型薬物送達インプラント
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN105431135A (zh) * 2013-11-08 2016-03-23 泰尔克斯公司 用于治疗手术并发症的聚合给药系统
WO2015085251A1 (en) * 2013-12-06 2015-06-11 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
US20160310417A1 (en) * 2013-12-20 2016-10-27 Emory University Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
CN106604695B (zh) * 2014-09-06 2018-10-23 整体生物系统有限责任公司 用于在眼中实现持续药物释放的方法和生物相容性组合物
JP6914931B2 (ja) 2015-07-23 2021-08-04 アエリエ ファーマシューティカルズ インコーポレイテッド 眼の症状の治療のための医薬組成物、硝子体内インプラント及び医薬品の製造におけるそれらの使用
WO2017120600A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
US20180117148A1 (en) * 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
CA3054497A1 (en) * 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
MX2021010599A (es) 2019-03-05 2021-12-10 Aerie Pharmaceuticals Inc Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9798189B2 (en) * 2010-06-22 2017-10-24 Toyobo Co., Ltd. Liquid crystal display device, polarizer and protective film
EP2704748A1 (en) * 2011-05-02 2014-03-12 DSM IP Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
EP3233067A1 (en) * 2014-12-18 2017-10-25 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs

Also Published As

Publication number Publication date
EP3934646A4 (en) 2022-12-14
EP3934646A1 (en) 2022-01-12
US20200306182A1 (en) 2020-10-01
AU2020232314A1 (en) 2021-09-30
JP2025004160A (ja) 2025-01-14
WO2020181060A1 (en) 2020-09-10
AU2020232314B2 (en) 2023-10-12
KR20210135560A (ko) 2021-11-15
MX2025002265A (es) 2025-04-02
CN113784727A (zh) 2021-12-10
BR112021017436A2 (pt) 2021-11-16
JP2025004161A (ja) 2025-01-14
JP7570342B2 (ja) 2024-10-21
US12478577B2 (en) 2025-11-25
JP2022523548A (ja) 2022-04-25
CA3132635A1 (en) 2020-09-10
CN113784727B (zh) 2024-03-29
CN118286445A (zh) 2024-07-05
CN118304422A (zh) 2024-07-09
MX2021010599A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
AU2020232314C1 (en) Pharmaceutical compositions for treating ocular diseases or disorders
US11116776B2 (en) Intravitreal drug delivery systems for the treatment of ocular conditions
JP5608138B2 (ja) 生分解性チロシンキナーゼインヒビター硝子体内インプラント
TWI377956B (en) Biodegradable intravitreal tyrosine kinase implants
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP6546194B2 (ja) 眼性状態を処置するための前房内インプラント
JP2016513109A (ja) 持続型薬物送達インプラント
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
CN120897764A (zh) 包含阿西替尼多晶型物iv的眼部植入物
AU2016269432A1 (en) Biodegradable introcular tyrosine kinase inhibitor implants
JP2023500035A (ja) 高いガラス転移温度を有するポリエステルアミドコポリマー

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 DEC 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 DEC 2023

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALCON INC.

Free format text: FORMER OWNER(S): AERIE PHARMACEUTICALS, INC.